The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma

Cancer

Volumn 88, Issue 6, 2000, Pages 1378-1383

  Gatalica, Zoran ^a,b   Lele, Subodh M ^a   Rampy, B Alan ^a   Norris, Brent A ^a  

^a John Sealy Hospital and John Sealy Annex   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Breast; Carcinoma; Fhit; Hyperplasia

Indexed keywords

GENE PRODUCT; PROTEIN FHIT; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER CLASSIFICATION; CANCER GROWTH; CANCER STAGING; CHROMOSOME 3P; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACID ANHYDRIDE HYDROLASES; BREAST; BREAST NEOPLASMS; CARCINOMA; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHI-SQUARE DISTRIBUTION; CHROMOSOMES, HUMAN, PAIR 13; COHORT STUDIES; DISEASE PROGRESSION; EPITHELIUM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MASTECTOMY; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; PRECANCEROUS CONDITIONS; PROTEINS;

EID: 0034653840     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000315)88:6<1378::AID-CNCR15>3.0.CO;2-I     Document Type: Article

References (30)

1. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996;84: 587-97.
2. Siprashvili Z, Sozzi G, Barnes LD, McCue PA, Robinson AK, Eryomin V, et al. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 1997;94: 13771-6.
3. 3-triphosphate hydrolase. Biochemistry 1996;35:11529-35.
4. nA), a novel class of signalling molecules? FEBS Lett 1998;427:157-63.
5. 4A ratio in human cell cultures. FEBS Lett 1997;415: 160-2.
6. Muller CY, O'Boyle JD, Fong KM, Wistuba II, Biesterveld E, Ahmadian M, et al. Abnormalities of fragile histidine triad genomic and complementary DNAs in cervical cancer: association with human papillomavirus type. J Natl Cancer Inst 1998;90:433-9.
7. Otterson GA, Xiao GH, Geradts J, Jin F, Chen W, Niklinska W, et al. Protein expression and functional analysis of the FHIT gene in human tumor cells. J Natl Cancer Inst 1998;90:426-32.
8. Knudson AG. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 1985;45:1437-43.
9. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9:138-41.
10. Beckmann MW, Niederacher D, Schnurch HG, Gusterson BA, Bender HG. Multistep carcinogenesis of breast cancer and tumor heterogeneity. J Mol Med 1997;75:429-39.
11. Tavassoli FA. Pathology of the breast. Norwalk: Appleton & Lange, 1992:155-191.
12. Rosai J. Borderline epithelial lesions of the breast. Am J Surg Pathol 1991;15:209-21.
13. Ellis IO, Pinder SE, Lee AHS, Elston CW. A critical appraisal of existing classification systems of epithelial hyperplasia and in situ neoplasia of the breast with proposal for future methods of categorization: where are we going? Semin Diagn Pathol 1999;16:202-8.
14. Eyzaguirre EJ, Miettinen M, Norris BA, Gatalica Z. Different immunohistochemical patterns of Fhit protein expression in renal neoplasms. Mod Pathol 1999;12:979-83.
15. Huebner K, Garrison PN, Barnes LD, Croce CM. The role of the FHIT/FRA3B locus in cancer. Annu Rev Genet 1998;32: 7-31.
16. McCarty KS, Miller LS, Cox EB, Konrath J, McCarty KS. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985;109:716-21.
17. Katz R, Patel S, Sneige N, Fritsche HA, Hortobagyi GN, Ames FC, et al. Comparison of immunocytochemical and biochemical assays for estrogen receptor in fine needle aspirates and histologic sections from breast carcinoma. Breast Cancer Res Treat 1990;15:191-203.
18. Stokes ME, Davis CS, Koch GG. Categorical data analysis using the SAS system. Cary, NC: SAS Institute Inc., 1995:95-150.
19. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985; 312:146-51.
20. Fitzgibbons PL, Henson DE, Hutter RVP. Benign breast changes and the risk for subsequent breast cancer. Arch Pathol Lab Med 1998;122:1053-5.
21. Matsumoto S, Kasumi F, Sakamoto G, Onda M, Nakamura Y, Emi M. Detailed deletion mapping of chromosome arm 3p in breast cancers: a 2-cM region on 3p14.3-21.1 and 5-cM region on 3p24.3-25.1 commonly deleted in tumors. Genes Chromosomes Cancer 1997;20:268-74.
22. Teixera MR, Pandis N, Bardi G, Andersen JA, Heim S. Karyotypic comparison of multiple tumorous and macroscopically normal surrounding tissue samples from patients with breast cancer. Cancer Res 1996;56:855-9.
23. Teixera MR, Pandis N, Gerdes AM, Dietrich CU, Bardi G, Andersen JA, et al. Cytogenetic abnormalities in an in situ ductal carcinoma and five prophylactically removed breasts from members of a family with hereditary breast cancer. Breast Cancer Res Treat 1996;38:177-82.
24. Pandis N, Bardi G, Mitelman F, Heim S. Deletion of short arm of chromosome 3 in breast tumors. Genes Chromosomes Cancer 1997;18:241-5.
25. Ingvarsson S, Agnarsson BA, Sigbjornsdottir BI, Kononen J, Kallioniemi OP, Barkardottir RB, et al. Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas. Cancer Res 1999;59:2682-9.
26. Druck T, Berk L, Huebner K. FHITness and cancer. Oncol Res 1998;10:341-5.
27. Depowski PL, Rosenthal SI, Brien TP, Croce CM, Ross JS. Prognostic significance of Fhit protein expression in breast cancer. Mod Pathol 1999;12:19A.
28. Bieche I, Latil A, Becette V, Lidereau R. Study of FHIT transcripts in normal and malignant breast tissue. Genes Chromosomes Cancer 1998;23:292-9.
29. Ahmadian M, Wistuba II, Fong KM, Behrens C, Kodagoda D, Saboorian MH, et al. Analysis of the Fhit gene and FRA3B in sporadic breast cancer, preneoplastic lesions and familial breast cancer probands. Cancer Res 1997;57:3664-8.
30. Man S, Ellis I, Sibbering M, Blamey RW, Brook JD. High levels of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and grade I tubular invasive breast cancers. Cancer Res 1996;56:5484-9.